全文获取类型
收费全文 | 199260篇 |
免费 | 2159篇 |
国内免费 | 176篇 |
专业分类
耳鼻咽喉 | 1313篇 |
儿科学 | 7104篇 |
妇产科学 | 3413篇 |
基础医学 | 19107篇 |
口腔科学 | 2141篇 |
临床医学 | 14210篇 |
内科学 | 37150篇 |
皮肤病学 | 1133篇 |
神经病学 | 19347篇 |
特种医学 | 9568篇 |
外科学 | 32353篇 |
综合类 | 2347篇 |
一般理论 | 5篇 |
预防医学 | 19040篇 |
眼科学 | 3158篇 |
药学 | 10788篇 |
中国医学 | 653篇 |
肿瘤学 | 18765篇 |
出版年
2023年 | 174篇 |
2022年 | 392篇 |
2021年 | 748篇 |
2020年 | 445篇 |
2019年 | 627篇 |
2018年 | 22461篇 |
2017年 | 17805篇 |
2016年 | 20000篇 |
2015年 | 1563篇 |
2014年 | 1760篇 |
2013年 | 1977篇 |
2012年 | 8846篇 |
2011年 | 22808篇 |
2010年 | 19838篇 |
2009年 | 12486篇 |
2008年 | 21037篇 |
2007年 | 23304篇 |
2006年 | 2121篇 |
2005年 | 3726篇 |
2004年 | 4913篇 |
2003年 | 5615篇 |
2002年 | 3736篇 |
2001年 | 454篇 |
2000年 | 515篇 |
1999年 | 315篇 |
1998年 | 437篇 |
1997年 | 418篇 |
1996年 | 281篇 |
1995年 | 272篇 |
1994年 | 226篇 |
1993年 | 187篇 |
1992年 | 161篇 |
1991年 | 181篇 |
1990年 | 210篇 |
1989年 | 149篇 |
1988年 | 122篇 |
1987年 | 109篇 |
1986年 | 78篇 |
1985年 | 93篇 |
1984年 | 97篇 |
1983年 | 65篇 |
1982年 | 70篇 |
1981年 | 45篇 |
1980年 | 72篇 |
1977年 | 33篇 |
1974年 | 33篇 |
1938年 | 60篇 |
1934年 | 30篇 |
1932年 | 59篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
951.
Kadri Altundag Ozden Altundag Paolo Morandi Mehmet Gunduz 《Journal of clinical oncology》2005,23(10):2435-6; author reply 2436
952.
Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). 总被引:5,自引:0,他引:5
Lindsay M Morton Patricia Hartge Theodore R Holford Elizabeth A Holly Brian C H Chiu Paolo Vineis Emanuele Stagnaro Eleanor V Willett Silvia Franceschi Carlo La Vecchia Ann Maree Hughes Wendy Cozen Scott Davis Richard K Severson Leslie Bernstein Susan T Mayne Fred R Dee James R Cerhan Tongzhang Zheng 《Cancer epidemiology, biomarkers & prevention》2005,14(4):925-933
BACKGROUND: The International Lymphoma Epidemiology Consortium (InterLymph) provides an opportunity to analyze the relationship between cigarette smoking and non-Hodgkin lymphoma with sufficient statistical power to consider non-Hodgkin lymphoma subtype. The results from previous studies of this relationship have been inconsistent, likely due to the small sample sizes that arose from stratification by disease subtype. To clarify the role of cigarette smoking in the etiology of non-Hodgkin lymphoma, we conducted a pooled analysis of original patient data from nine case-control studies of non-Hodgkin lymphoma conducted in the United States, Europe, and Australia. METHODS: Original data were obtained from each study and uniformly coded. Risk estimates from fixed-effects and two-stage random-effects models were compared to determine the impact of interstudy heterogeneity. Odds ratios (OR) and 95% confidence intervals (95% CI) were derived from unconditional logistic regression models, controlling for study center, age, sex, and race. RESULTS: In our pooled study population of 6,594 cases and 8,892 controls, smoking was associated with slightly increased risk estimates (OR, 1.07; 95% CI, 1.00-1.15). Stratification by non-Hodgkin lymphoma subtype revealed that the most consistent association between cigarette smoking and non-Hodgkin lymphoma was observed among follicular lymphomas (n = 1452). Compared with nonsmokers, current smokers had a higher OR for follicular lymphoma (1.31; 95% CI, 1.12-1.52) than former smokers (1.06; 95% CI, 0.93-1.22). Current heavy smoking (> or = 36 pack-years) was associated with a 45% increased OR for follicular lymphoma (1.45; 95% CI, 1.15-1.82) compared with nonsmokers. CONCLUSIONS: Cigarette smoking may increase the risk of developing follicular lymphoma but does not seem to affect risk of the other non-Hodgkin lymphoma subtypes we examined. Future research is needed to determine the biological mechanism responsible for our subtype-specific results. 相似文献
953.
Riccardo Valdagni Corrado Italia Paolo Montanaro Angelo Lanceni Paola Lattuada Tiziana Magnani Claudio Fiorino Alan Nahum 《Radiotherapy and oncology》2005,75(1):74-82
BACKGROUND AND PURPOSE: The objectives of the current study were to compare genito-urinary (GU) and gastro-intestinal (GI) toxicities as well as biochemical control (bRFS) in prostate cancer, utilizing conventional (2.0 Gy daily) (STD) or hyperfractionated (HFX) conformal irradiation (CRT). HFX (1.2 Gy BID) was chosen as a radiobiological method to try to reduce long term sequelae without compromising local control. PATIENTS AND METHODS: Three-hundred-and-seventy consecutive patients (pts) entered this prospective, non-randomized trial in the period January 1993-January 2003; 209 were treated with STD and 161 with HFX CRT. All were evaluable for acute toxicity analysis, 179 (STD) and 151 pts (HFX) being evaluable for late sequelae and bRFS analyses. Pt characteristics were not statistically different in the two groups. CRT consisted of a 4-field technique for prostate and/or pelvic nodes and a 5-field boost with rectal shielding. Median doses were 74 and 79.2 Gy for STD and HFX patients respectively, the latter dose being isoeffective for tumour control assuming alpha/beta=10 (EQD(2)=73.9 Gy). Median follow-up was 29.4 months (25.2 mos for STD; 37.7 mos for HFX; P<0.01). The two regimens were compared in terms of acute and late GU and GI toxicities and 5-year bRFS by univariate and multivariate analyses. RESULTS: Acute grade> or =2 GU toxicity was higher in the STD group (48.6% versus 37.3% in HFX, P=0.03), while no significant difference was found for acute GI toxicity. Late grade> or =2 GU and GI toxicities were lower in the HFX group (5-year actuarial rate: GU: 10.1% versus 20.3%, P=0.05; GI: 6.0% versus 10.6%, P=0.18). Five-year bRFS were 70% (+/-13.8%, 95% CI) and 82.6% (+/-7.2%) for STD and HFX, respectively (P=0.44); a trend favouring HFX was found in the subgroup of pts who did not receive hormonal therapy (5-year bRFS: 85.9%+/-12.4% versus 63.9%+/-23.8%, P=0.15). Multivariate analysis revealed only risk groups and age statistically related to bRFS but not fractionation regimen. Using the Nahum-Chapman TLCP model and prostate parameter set, which includes hypoxia, the TLCPs are approximately equal for the two regimens, whereas assuming alpha/beta=1.5 and no hypoxia we obtain 73% for the STD group but only 36% for the HFX group. CONCLUSIONS: As expected from radiobiological considerations, HFX reduces GI and GU late toxicities. Concerning early bRFS, our clinical findings suggest that HFX is no less effective than STD when delivering an isoeffective (alpha/beta=10) dose. Despite the relatively short follow-up, this result appears to be inconsistent with a low alpha/beta ratio for prostate cancer. 相似文献
954.
Andrew G Rundle Paolo Vineis Habibul Ahsan 《Cancer epidemiology, biomarkers & prevention》2005,14(8):1899-1907
Past discussions of the relative strengths of nested case-control and case-cohort designs have not fully considered cohorts with stored biological samples in which biomarker analyses are planned. Issues related to biomarker analyses can affect an investigator's choice of design and the conduct of these two designs. The key issues identified are effects of analytic batch, long-term storage, and freeze-thaw cycles on biomarkers. In comparison with the nested case-control design, the case-cohort design is less able to handle these challenges. Problems arise because most implementations of the case-cohort design do not allow for simultaneous evaluation of biomarkers in cases and reference group members, and there is no matching. By design, the nested case-control study controls for storage duration and the batching of biological samples from cases and controls is logistically simple. The allowance for matching also means that subjects can be matched on the number of freeze-thaw cycles experienced by the biological sample. However, the matching generates complex data sets that can be more difficult to analyze, and the costly biomarker data generated from the controls has few uses outside of testing the specific hypotheses of the study. In addition, because the same subject can serve as a control and a case, or multiple times as a control, biomarker analyses and sample batching can be more complex than initially anticipated. However, in total, of the two designs, the nested case-control study is better suited for studying biomarkers that can be influenced by analytic batch, long-term storage, and freeze-thaw cycles. 相似文献
955.
Serum PDGF-AB in pleural mesothelioma. 总被引:2,自引:0,他引:2
Rosa Filiberti Paola Marroni Monica Neri Andrea Ardizzoni Pier Giacomo Betta Mara A Cafferata Pier Aldo Canessa Riccardo Puntoni Giovanni Paolo Ivaldi Michela Paganuzzi 《Tumour biology》2005,26(5):221-226
Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean+2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR=1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM. 相似文献
956.
Brittany C. Thomas Stephen N. Thibodeau Noralane M. Lindor 《Current colorectal cancer reports》2005,1(2):103-109
Referrals to genetics services are becoming increasingly common for patients who are diagnosed with early-onset colorectal
cancer (CRC) or patients who have a family history of CRC. Microsatellite instability (MSI) testing and immunohistochemical
analysis (IHC) of the patient’s tumor tissue, which assess indirectly the cellular status of DNA mismatch repair, have proven
important tools for geneticists and genetic counselors to determine whether or not these individuals may be at risk for an
inherited cancer syndrome, Lynch syndrome (a subset of hereditary nonpolyposis colorectal cancer). The application of tumor
MSI/ IHC also extends to the group of providers involved in the diagnosis and management of CRC, demonstrating the growing
clinical applicability of MSI/IHC testing. This review discusses the clinical utility of MSI/IHC analysis, including its benefits
and limitations, and addresses some of the current debates surrounding testing. 相似文献
957.
The vast majority of new cases of colorectal cancer, the second most common cause of death in men and women in the United
States, are attributable to environmental rather than genetic causes. Recent research has clarified inconsistencies in the
literature and has explored new pathways through which risk factors may act. This review discusses newly published, selected
interesting and important findings in colorectal cancer etiology; these include postmenopausal hormone use, nonsteroidal anti-inflammatory
drug use, obesity, physical activity, diet, and other confirmed epidemiologic associations. This research provides insight
into mechanisms and offers opportunities for prevention. 相似文献
958.
IGF-I, IGFBP-3 and breast cancer in young women: a pooled re-analysis of three prospective studies. 总被引:2,自引:0,他引:2
Sabina Rinaldi Paolo Toniolo Paola Muti Eva Lundin Anne Zeleniuch-Jacquotte Alan Arslan Andrea Micheli Per Lenner Laure Dossus Vittorio Krogh Roy E Shore Karen L Koenig Elio Riboli P?r Stattin Franco Berrino G?ran Hallmans Annekatrin Lukanova Rudolf Kaaks 《European journal of cancer prevention》2005,14(6):493-496
Prospective cohort studies on breast cancer risk among premenopausal women and insulin-like growth factor I (IGF-I) concentrations have so far included only few cases, and have shown inconsistent relative risk estimates. We pooled 220 cases of breast cancer diagnosed before age 50, and 434 control subjects, from three prospective studies in New York (USA), Ume? (Northern Sweden) and Milan (Italy), and we measured IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) with common enzyme-linked immunosorbent assays. Overall, IGF-I and IGFBP-3 measurements obtained by the common method showed a positive but not significant relationship with breast cancer risk (odds ratios (ORs) 0.90 [95% confidence intervals (95% CI) 0.50-1.62], 1.63 [0.89-2.97], 1.46 [0.78-2.73] and 1.41 [0.75-2.63] for quintiles of IGF-I, and ORs 0.98 [0.54-1.75], 1.06 [0.59-1.91], 1.04 [0.58-1.87] and 1.77 [0.97-3.24] for quintiles of IGFBP-3). Our results give only moderate support for an association of blood IGF-I with breast cancer risk in young women. 相似文献
959.
960.